Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Shares Outstanding (Weighted Average) (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Shares Outstanding (Weighted Average) for 16 consecutive years, with $14.3 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) fell 2.59% to $14.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.3 million through Dec 2025, down 2.59% year-over-year, with the annual reading at $14.3 million for FY2025, 2.59% down from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $14.3 million at Anika Therapeutics, roughly flat from $14.4 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $14.8 million in Q2 2024, with the low at $14.3 million in Q1 2025.
  • Average Shares Outstanding (Weighted Average) over 5 years is $14.5 million, with a median of $14.6 million recorded in 2022.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 1.49% in 2022, then decreased 3.2% in 2025.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $14.4 million in 2021, then grew by 1.11% to $14.6 million in 2022, then rose by 0.65% to $14.7 million in 2023, then rose by 0.44% to $14.7 million in 2024, then decreased by 2.59% to $14.3 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $14.3 million, $14.4 million, and $14.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.